Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- BioLight announced today it had obtained the worldwide rights (excluding Israel and Italy) for the manufacturing, distribution, marketing and sales of a new eye drop product for the treatment of dry eye syndrome and other ophthalmic indications.
- RegeneRx Biopharmaceuticals, Inc. recently released positive results from its second clinical trial evaluating RGN-259 for the treatment of dry eye, sponsored by ReGenTree LLC, its U.S. joint venture with GtreeBNT in Korea.
- Aldeyra Therapeutics, Inc. recently reported a Phase II clinical trial in of topical ocular NS2 — a first-in-class aldehyde trap — demonstrated activity comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active noninfectious anterior uveitis.
- Imprimis Pharmaceuticals, Inc. recently launched two new products at the recent American Society of Cataract and Refractive Surgery (ASCRS) meeting — the patent-pending IV Free™ MKO Melt™ (midazolam, ketamine and ondansetron) compounded conscious sedation formulation and new triple combination eye drop Pred-Moxi-Nepafenac (prednisone acetate, moxifloxacin hydrocholoride, and nepafenac).
- Biogen has announced a collaboration with the University of Pennsylvania to advance gene therapy and gene editing technologies, with a primary focus on developing therapeutic approaches for the eye, skeletal muscle and central nervous system.